Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Voxelotor Dose Escalation in Sickle Cell Disease
NCT04247594Phase 2Terminated
- Sponsor
- Pfizer
- Start
- Jan 2020
- Primary completion
- Jun 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of voxelotor in sickle cell disease (SCD) (4 arms), sponsored by Pfizer. Primary endpoint: Treatment-emergent Adverse Events at 300 days. Started Jan 2020; status: terminated.
02
Drugs
voxelotor
03
Conditions
sickle cell disease (SCD)
Beyond the preview
Go deeper on NCT04247594.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04247594.